GSK Licenses Five Prime Therapeutics’ Respiratory Disease IPBy
GlaxoSmithKline (GSK) has licensed intellectual property from Five Prime Therapeutics, a South San Francisco, California-based clinical-stage biotechnology company, related to a target for respiratory diseases that is under a research collaboration between the two companies. The execution of the license has triggered a $1.5 million payment to Five Prime by GSK.
The target compound is one of several potential targets that Five Prime has identified under the collaboration, established in 2012. GSK will further develop and commercialize products that incorporate or target the licensed protein target as well as fund preclinical studies, clinical development, manufacturing, and commercialization. Five Prime has a library of approximately 5,700 extracellular proteins for protein therapeutics and is eligible to receive up to $92.75 million in contingent milestone payments.
The original scope of the collaboration focused on identifying therapeutic approaches for refractory asthma and chronic obstructive pulmonary disease, but this was expanded in April 2014 to include two additional respiratory disease programs.
Source: Five Prime Therapeutics